A detailed history of Privium Fund Management B.V. transactions in Uni Qure N.V. stock. As of the latest transaction made, Privium Fund Management B.V. holds 744,916 shares of QURE stock, worth $12.9 Million. This represents 0.92% of its overall portfolio holdings.

Number of Shares
744,916
Previous 640,416 16.32%
Holding current value
$12.9 Million
Previous $2.87 Million 27.99%
% of portfolio
0.92%
Previous 0.81%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$3.78 - $10.12 $395,010 - $1.06 Million
104,500 Added 16.32%
744,916 $3.67 Million
Q2 2024

Jul 31, 2024

BUY
$4.39 - $5.43 $269,989 - $333,950
61,501 Added 10.62%
640,416 $2.87 Million
Q1 2024

Apr 30, 2024

BUY
$4.82 - $6.93 $649,576 - $933,935
134,767 Added 30.34%
578,915 $3.01 Million
Q4 2023

Feb 13, 2024

BUY
$5.63 - $8.27 $915,111 - $1.34 Million
162,542 Added 57.72%
444,148 $3.01 Million
Q3 2023

Nov 06, 2023

BUY
$6.71 - $11.83 $115,868 - $204,280
17,268 Added 6.53%
281,606 $1.89 Million
Q2 2023

Jul 25, 2023

SELL
$11.12 - $22.2 $410,995 - $820,512
-36,960 Reduced 12.27%
264,338 $3.03 Million
Q4 2022

Feb 02, 2023

BUY
$18.12 - $27.32 $1.13 Million - $1.7 Million
62,300 Added 26.07%
301,298 $6.83 Million
Q3 2022

Nov 03, 2022

SELL
$16.98 - $25.54 $3.78 Million - $5.68 Million
-222,591 Reduced 48.22%
238,998 $4.28 Million
Q2 2022

Jul 28, 2022

SELL
$13.15 - $20.45 $416,066 - $647,038
-31,640 Reduced 6.41%
461,589 $8.6 Million
Q1 2022

May 10, 2022

BUY
$14.54 - $21.5 $337,269 - $498,714
23,196 Added 4.93%
493,229 $8.91 Million
Q4 2021

Feb 09, 2022

BUY
$20.24 - $36.01 $9.51 Million - $16.9 Million
470,033 New
470,033 $9.81 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.